Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593703 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2675632 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2675628 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2947991 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2947993 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL22202893 | 0.85 | CTSK (0.50) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL3593707 | 0.80 | PPARA (0.42) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL4671738 | 0.80 | PPARA (0.64) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL5142486 | 0.80 | PPARA (0.64) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL4671732 | 0.80 | PPARA (0.64) | PPARAPPARGPPARDMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144112-A9 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | PPARA 2758/4885PPARG 2849/4885PPARD 3372/4885 |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.